Climbing the blockbuster mountain, Roche/AbbVie team heralds a win in frontline CLL PhIII
AbbVie $ABBV and Roche have posted a goal on their pivotal combination of Venclexta and Gazyva for frontline cases of chronic lymphocytic leukemia, which should help boost their blockbuster dreams for added revenue.
We don’t have the hard data yet, but the companies are already hustling their combo data to regulators in hopes of expanding the market for Venclexta.
In this study their combo beat out Gazyva plus chlorambucil in producing a solid advantage for progression-free survival. That should give the company’s boosters encouragement in believing this drug can push past the $2 billion a year mark toward $3 billion in peak sales — which would make this drug a big contributor to both of their bottom lines.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.